【默沙东终止开发抗TIGIT抗体和抗LAG-3抗体】金十数据12月17日讯,12月16日,默沙东宣布终止开发抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab。Vibostolimab(MK-7684)通过阻断TIGIT受体与其配体(CD112和CD155)结合来恢复T细胞的肿瘤杀伤活性。Favezelimab(MK-4280)通过阻断LAG-3受体与其主要配体、主要组织相容性复合体(MHC)II类分子结合来恢复T细胞效应器功能。在预先计划的分析中,KeyVibe-003研究和KeyVibe-007研究都达到了OS这一主要终点的预先设定的无效标准。默沙东表示,固定剂量组合治疗组发生的免疫相关不良事件比帕博利珠单抗单药治疗组多。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.